However, the response rates of therapy with PD-1 blockade among advanced NSCLC patients are highly heterogeneous, ranging from approximately 10–50% (Hirsch et al. 2019; Garon et al. 2015), leading to an unmet need for improving clinical outcomes. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.